Keywords: Cortex, Ampakine, Valeant, Biovail, 2010 financial results
Cortex reacquires all Ampakine compounds, IP and rights from Valeant; cuts loss
Article | 22 March 2011
California, USA-based neuroscience company Cortex Pharmaceuticals (OTCBB: CORX.OB)) has entered into an agreement with Biovail Laboratories International, a wholly-owned ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
